Abbott Slightly Raises Profit Forecast on Strong Medical Device Sales
(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong sales of its medical devices including its glucose-monitoring products.
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...
On Wednesday, Abbott Laboratories (NYSE:ABT) reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating ...
On Wednesday, Abbott Laboratories (ABT) stock saw a modest uptick, ending the day at $117.82 which represents a slight increase of $1.77 or 1.53% from the prior close of $116.05. The stock opened at ...
Bernstein analyst Lee Hambright maintained a Buy rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target ...
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings ...
Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...
3d
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) today and set a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback